In this real-world study, CD19 CAR-T-cell therapy in patients with R/R DLBCL resulted in meaningful clinical benefits, particularly in those achieving CR and receiving Axi-cel in earlier treatment lines. Here, CD19 is linked to diffuse large B-cell lymphoma.